Cigarette smoke alters the invariant natural killer

T cell function and may inhibit anti-tumor responses by Hogan, Andrew et al.
ava i l ab l e a t www.sc i enced i r ec t . com
C l i n i ca l Immuno logy
www.e l sev i e r . com/ loca te /yc l im
Clinical Immunology (2011) 140, 229–235Cigarette smoke alters the invariant natural killer
T cell function and may inhibit anti-tumor responses
Andrew E. Hogana,⁎, Michelle A. Corrigana, Vincent O'Reilly b,
Gadintshware Gaoatswea, Jean O'Connell a, Derek G. Dohertyb,
Lydia Lyncha,c, Donal O'Sheaa,da Obesity Immunology Group, Education and Research Centre, St Vincents University Hospital, UCD, Dublin 4, Ireland
b Human Immunology Group, Institute of Molecular Medicine, St James Hospital, TCD, Dublin 8, Ireland
c Hematology and Oncology Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, USA
d St Columncille's Hospital, Loughlinstown, Dublin, Ireland
Received 4 October 2010; accepted with revision 21 January 2011
Available online 2 February 2011Abbreviations: αGalCer, α-Galacto
smoke extract, iNKT, Invariant natural
blood mononuclear cells
⁎ Corresponding author at: Obesity Im
and Research Centre, University Co
University Hospital Dublin 4, Ireland.
E-mail address: Andrew.Hogan.3@u
1521-6616/$ - see front matter © 201
doi:10.1016/j.clim.2011.01.011KEYWORDS
iNKT cells;
Cigarette smoke;
Anti-tumor responses
Abstract Invariant natural killer T (iNKT) cells are a minor subset of human T cells which express
the invariant T cell receptor Vα24 Jα18 and recognize glycolipids presented on CD1d. Invariant NKT
cells are important immune regulators and can initiate anti-tumor responses through early potent
cytokine production. Studies show that iNKT cells are defective in certain cancers. Cigarette smoke
contains many carcinogens and is implicated directly and indirectly in many cancers. We
investigated the effects of cigarette smoke on the circulating iNKT cell number and function. We
found that the iNKT cell frequency is significantly reduced in cigarette smoking subjects. Invariant
NKT cells exposed to cigarette smoke extract (CSE) showed significant defects in cytokine
production and the ability to kill target cells. CSE inhibits the upregulation of CD107 but not CD69 or
CD56 on iNKT cells. These findings suggest that CSE has a specific effect on iNKT cell anti-tumor
responses, which may contribute to the role of smoking in the development of cancer.
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Smoking is the main cause of preventable morbidity and
mortality in the world [1]. Carcinogens from cigarette smoke
can lead directly to lung cancer [2] and are implicated in
several other malignancies such as bladder, cervix, stomach,
liver and kidney [3]. In addition to the increased cancer risk,
smokers have increased susceptibility to infections [4] and a
marked increase in autoimmune disorders such as rheuma-
toid arthritis [5].
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have an increased incidence of cancer [6]. Circulating
natural killer (NK) cell number and anti-tumor activity are
reduced in smokers compared to non-smokers [7,8]. We have
previously demonstrated that cigarette smoke extract (CSE)
reduces the NK cell function in vitro in a dose-dependent
manner [9]. These studies suggest that cigarette smoke
alters the host immunity, enabling tumor cells and pathogens
to evade immune responses and increasing susceptibility to
autoimmune conditions.
Invariant natural killer T (iNKT) cells are a rare subset of
human innate T cells defined by their expression of the
invariant T cell receptor (TCR) Vα24 Jα18 and NK-like
surface molecules [10]. The invariant TCR recognizes
glycolipid antigen such as the marine sponge-derived
antigen αGalactosylceramide (αGalCer) [11,12]. Invariant
NKT cells are potent immunomodulatory cytokine secreting
cells, capable of simultaneously producing IFN-γ and IL-4
when stimulated [13,14]. Invariant NKT cells respond
rapidly to antigen (Ag) or infection (b2 h) and can activate
other cells of the innate and adaptive immune systems
including NK cells [15]. Invariant NKT cells are implicated in
the prevention of tumor growth and the eradication of
existing tumors in mice [16,17]. In humans the number of
circulating and tissue-resident iNKT cells are reduced in
cancer [18–20]. Currently iNKT cells are the basis of
numerous phase I and II oncology trials [21–24]. As well
as their ability to rapidly produce immunomodulating
cytokines, iNKT cells have been reported to lyse target
tumor cells in vitro [25,26].
The objective of this study was to investigate if cigarette
smoke affects the function of iNKT cells. We investigated the
levels of circulating iNKT cells in a cohort of healthy subjects
who smoke 20 cigarettes daily compared to age-matched
non-smoking individuals. We also investigated both the iNKT
cell production of immune modulating cytokines and their
ability to efficiently lyse tumor cells before and after
exposure to CSE.2. Materials and methods
2.1. Ethics statement
The ethics committee at St. Vincent's University Hospital,
Dublin granted approval for all aspects of this study. Blood
samples were obtained with informed written consent from
healthy individuals who smoked 20 cigarettes daily and age-
matched controls.2.2. Preparation of PBMC cells
100 mls of venous blood was collected in heparinized
collection tubes. PBMCs were isolated by density centrifu-
gation on Lymphoprep (Nycomed, Norway) at 400 g for
25 min. Cells were washed twice and cell pellets were re-
suspended in 1 ml of RPMI 1640 medium, and cell yields and
viability were assessed by ethidium bromide/acridine
orange staining. The cell suspension was adjusted to
100×106 cells/ml in Miltenyi separation buffer (Miltenyi
Biotech, UK).2.3. Generation of iNKT cell lines
iNKT cells were isolated from PBMC cell suspensions by
positive selection of anti-6b11 magnetic bead (Miltenyi
Biotech, UK) labeled cells (as per manufacturer's instruc-
tions). The purified iNKT cell suspensions were stained with
6B11 PE and CD3 PE-CY5 monoclonal antibodies (mAb) (BD
Biosciences, UK) for 30 min, before washing. The cells were
then sorted by high speed FACS for double positive cells
(6B11+ CD3+) using a MoFlo FACS (Dako Cytomation, USA).
1000 sorted cells were cultured per 96-round bottomed plate
well in complete RPMI medium with 150,000 irradiated PBMC
from 2 donors, 10 ng/ml of PHA (Sigma Aldrich, UK) and
250 U/ml of IL-2 (Immunotools, Germany). The PHA was
diluted out over 48 h using a complete RPMI with 250 U/ml of
IL-2. Media was replenished every 7–10 days and wells
divided when required.
2.4. Flow cytometric staining and analysis
Cells were stained with optimal amounts of the previously
titrated mAbs CD3, CD4, CD8, 6B11, CD56, CD69, CD107 and
relevant isotype controls (BD Biosciences, UK) and incubated
at 4 °C for 30 min. Cells were washed twice in pbs/pba and
resuspended in 1% PFA and acquired after a 10 min
incubation at 4 °C. Cells were analyzed using a FACSCalibur
flow cytometer and CellQuest Pro software (BD Biosciences).
Lymphocytes were gated (‘lymphogate’) by their density and
granularity using forward scatter and side scatter para-
meters, which contained 95% of peripheral lymphocytes. All
further analysis was performed on lymphocytes only. Thirty
thousand lymphocyte events were acquired in each case.
Frequencies were expressed as a percentage of lymphocytes
(or iNKT cells where appropriate).
2.5. Cigarette smoke extract
A system for generating cigarette smoke was developed
based upon a validated pump system described by Bernard
and colleagues [27], with modifications described by Cawood
et al. [28]. Smoke from four cigarettes was pumped through
a 30 ml RPMI culture medium. Ten puffs were pumped for
each cigarette, each puff contributing 35 ml of smoke, every
30 s, resulting in approximately 75% of the cigarette being
consumed, and the 350 ml of smoke extract was generated
per cigarette. Each milliliter of CSE contains 0.133 (4/30)
cigarette's worth of smoke-derived constituents. The resul-
tant CSE was sterilized by filtering through a 0.2-μm filter,
pH adjusted to 7.4, and then stored at −20 °C. The
cigarettes used were Marlboro Reds, Class A, rated as tar
10 mg, nicotine 0.8 mg, and carbon monoxide 10 mg.
Bernhard's validated volumetric calculations are based on
the assumption that a human generates 350 ml smoke with
each cigarette and has a blood volume of 6 liters. If that
person smokes 20 cigarettes per day, then each 300 ml
(6000/20) of blood contains the equivalent of one cigarette.
Therefore, each milliliter of blood contains 0.0033 (1/300)
cigarette's worth of smoke-derived constituents. By this
calculation, CSE can be considered to contain 40 times
(0.133/0.0033) the amount of smoke-derived constituents
than would be expected in the blood of a smoker who smokes
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equate to 20 cigarettes per day.2.6. Effect of CSE on iNKT phenotype
iNKT cell lines were cultured with or without CSE, either
alone or with CD1d transfected C1R cells at 1:1 ratio in the
presence or absence of 100 ng/ml of αGalCer for 24 h in a 96-
U bottom well plate at 37 °C. After 24 h cells were harvested
and stained with the mAbs, CD3, CD4, CD8, 6B11, CD56, CD69
and CD107 and acquired by flow cytometry using a
FACSCalibur and analyzed by Cell Quest2.7. Cytokine production assay
iNKT cell lines with or without CSE, were cultured alone or
co-cultured with CD1d transfected C1R cells at 1:1 ratio in
the presence or absence of 100 ng/ml of αGalCer for 72 h in a
96-U bottom well plate at 37 °C. After 24 h 125 μl of culture
supernatant was removed and assessed by ELISA (R&D
Systems, UK) and FlowCytomix (Bendermed Systems, UK)
for cytokine secretion. At 72 h the remaining supernatant
was assessed by ELISA.2.8. Cytotoxicity assay
CD1d transfected Hela target cells loaded with 100 ng/ml of
αGalCer were labeled with carboxyl fluorescein succinimidyl
ester (CFSE) and then added to the iNKT cell populations at
effector/target ratios 10:1. Cell co-cultures were incubated
at 37 °C for 4 h, in the absence or presence of CSE. Killing of
CFSE-labeled target cells was measured by staining with 7-
aminoactinomycin D (7-AAD) immediately after incubation
and by immediate analysis by flow cytometry (as per
manufactucter's instructions for the flow cytometry-based
Total Cytotoxicity & Apoptosis Detection Kit, Immunoche-
mistry, USA).Figure 1 Enumeration of iNKT cells in cigarette smoking individuals.
mononuclear cells from (A) a cigarette smoking subject and (B) a non
(C), scatter plot of iNKT frequencies in cigarette smoking cohort (blac
denotes the mean frequency (n=12). *=pb0.05.3. Results
3.1. Enumeration of iNKT cells in cigarette smoking
individuals
The frequency of circulating iNKT cells in cigarette smoking
subjects was assessed by flow cytometry using a combination
of the mAbs 6B11 PE and CD3 Per-Cp and compared to age
matched non-smoking cohort (Fig. 1). The frequency of iNKT
cells was significantly lower in the smoking cohort (mean of
0.22%) compared to the non-smoking cohort (0.33%)
(Pb0.05) the frequency of conventional T cells was
unchanged between smokers and non-smokers (data not
shown).
3.2. Cell yields and viability
There were no significant differences in cell viability after
exposure to cigarette smoke extract as determined by EB/AO
staining, in all cases viability exceeded 90% (data not
shown).
3.3. Generation of iNKT cell lines
Five iNKT cell lines were generated and were assessed by flow
cytometry to determine purity and phenotype of each (data
not shown). Each line was N99% positive for 6B11, CD3
illustrating an enrichment N200-fold. The expression of the
invariant TCR was also examined using the monoclonal
antibody pairing of Vα24 and Vβ11, all cells were positive for
Vα24 and for Vβ11. Of the 5 lines examined each had a mixed
expression of CD4, CD8 and CD4-CD8-subsets (data not shown).
3.4. Effect of CSE on iNKT phenotype
Upon iNKT cell activation, the cell up regulates functional
surface molecules. We aimed to investigate the effect of CSERepresentative flow cytometry dot plots showing peripheral blood
-smoking subject stained with the mAbs 6B11 PE and CD3 PE-Cy5.
k circles) and non-smoking cohort (unfilled circles), the black line
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CD69) and the killing associated molecule CD107. Invariant
NKT cells were co-cultured with CD1d-transfected C1R cells
loaded or unloaded with 100 ng/ml of αGalCer for 24 h in the
presence or absence of CSE. The expression of surface
molecules was examined by flow cytometry. The expression
of CD56, CD69 and CD107 was increased with the addition of
100 ng/ml of αGalCer. The presence of CSE only significantly
inhibited the up regulation of CD107 (pb0.05) (Fig. 2C). No
significant difference was observed in the surface expression
of CD56 or CD69 on the iNKT cells exposed to CSE and controls
(Fig. 2A–B).3.5. Effect of CSE on iNKT cytokine production
Invariant NKT cells were co-cultured with CD1d-transfected
C1R cells loaded or unloaded with 100 ng/ml of αGalCer for
24 and 72 h in the presence or absence of CSE. After 24 h
supernatants were assessed by Th1/Th2 flow cytomix assay
and ELISA (Fig. 3A and B). There were significant increases in
IFN-γ, TNF-α, IL-4 and IL-5 (pb0.005) secretion by iNKT cells
in the presence of αGalCer compared to the iNKT and CD1d-
transfected C1R cells in the absence of αGalCer (Fig. 3A
and B). The addition of CSE resulted in the significant
inhibition of IFN-γ secretion as detected by flow cytomix
assay (pb0.005) and ELISA (pb0.05) (Fig. 3A and B). CSE also
inhibited the secretion of IL-4 by iNKT cells compared to the
co-cultures in the presence of αGalCer when assessed by flow
cytomix assay (pb0.05) and ELISA (pb0.05) (Fig. 3A and B).
TNF-α and IL-5 secretion by iNKT cells was examined by the
flow cytomix assay and both were significantly increased in
the presence of αGalCer. The addition of CSE resulted in a
significant reduction in both TNF-α (pb0.005) and IL-5
(pb0.005) secretion after 24 h (Fig. 3A). After the 72 h
culture, supernatants were assessed by ELISA for IFN-γ and
IL-4 production. CSE had no effect on IFN-γ levels, with
comparable levels detected by ELISA between αGalCer withFigure 2 Effects of CSE inhibition on iNKT cell surface molecule ex
CD69 (B) and CD107 (C) by iNKT cell lines. The iNKT cells were cu
presence of 100 ng/ml αGalCer, with or without CSE for 24 h. Surface
are expressed percentage of iNKT cell expressing the molecule. Me
significant.and without CSE. Invariant NKT cells produced significantly
more IL-4 in the presence of CSE (pb0.05) than those
cultured without CSE (Fig. 3B).
3.6. Effect of CSE on iNKT cytotoxicity
Invariant NKT cells were co-cultured with CFSE-labeled
CD1d-transfected HeLa cells unloaded or loaded with
100 ng/ml of αGalCer for 4 h in the presence or absence of
CSE. After 4 h cell death was measured. Invariant NKT cells
lysed 28% of HeLa target cells. The addition of CSE resulted in
a reduction in the lysis to a mean of 17% (Fig. 4A). In the
presence of 100 ng/ml αGalCer, iNKT cells lysed 31% of HeLa
target cells. The addition of CSE resulted in a reduction in
the lysis to a mean of 21% (Fig. 4B), illustrating that CSE
reduces iNKT cell cytotoxicity.
4. Discussion
Cigarette smoke has strong associations with several cancers
and has previously been shown to inhibit important anti-
tumor innate immune responses by NK cells [3,9]. Invariant
NKT cells are important regulatory innate effector cells, with
the potential to elicit specific immune responses through
cytokine production [15,29]. This ability has highlighted iNKT
cells as an attractive target for cancer immunotherapy [31].
The effect of tumor environment on iNKT cell frequency has
been previously reported [18,19], however the effect of
other environmental factors such as CSE has not been
investigated. We aimed to determine if CSE altered the
iNKT cell anti-tumor activity. Our study suggests the effect
of CSE on iNKT cells is specific and reduces the population
number and function.
We investigated the frequency of circulating iNKT cells in
the peripheral blood of healthy cigarette-smoking subjects
and found a significant reduction in the iNKT cell number
compared to a non-smoking age-matched cohort (Fig. 1).pression. Bar graphs showing the surface expression of CD56 (A),
ltured with either CD1d transfected C1R cell in the absence or
marker expression was examined by flow cytometry. The values
an of 4 individual experiments. *=pb0.05, **=p0.005, ns=non
Figure 3 Investigation of CSE inhibition of iNKT cell derived cytokine secretion. Bar graphs showing IFN-γ, TNF-α, IL-5 and IL-4
secretion by iNKT cell lines after 24 h measured by Flow cytometry multiplex assay (A). Bar graphs showing IFN-γ, and IL-4 secretion by
iNKT cell lines after 24 and 72 h measured by ELISA (B). The iNKT cells were cultured with either CD1d transfected C1R cell in the
absence or presence of 100 ng/ml αGalCer, with or without CSE for 24 or 72 h. The values are expressed as fold increases in cytokine
production over the iNKT cell cultured with CD1d transfected C1R cells. Graphs are representative of 5 individual experiments.
*=pb0.05, **=pb0.005, ***=pb0.001.
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depletes iNKT cell number [18]. Our findings add cigarette
smoke as another environmental factor that leads to
depletion of iNKT cells. The finding that iNKT cell numbers
are reduced in cigarette-smoking subjects is novel. Reduced
iNKT cell number has also been reported in conditions
affected by smoking such as diabetes and head and neck
squamous cell carcinoma (HNSCC). In HNSCC low levels of
circulating iNKT cells predicted poor clinical outcomes in a
group of 47 patients compared to individuals with interme-
diate or high levels of circulating iNKT cells [30].
In addition to a reduction in iNKT cell number our study
also shows significant alteration in iNKT cell function. We
examined iNKT cell cytokine secretion in response to
αGalCer stimulation after 24 h in the absence or presence
of CSE. As previously described, iNKT cells secrete significant
amounts of IFN-γ and IL-4 simultaneously when stimulated
[13,14]. The addition of CSE resulted in a significant
reduction in the production of both cytokines after 24 h
(Fig. 3). We have previously reported that CSE inhibited
intracellular IFN-γ and increased IL-10 production by NK cells
[9]. This would bias the immune system towards a T helper
type 2 (Th2) response that does not have a significant anti-
tumor activity. Cigarette smoke therefore appears to have
multiple negative effects on the innate immune cells that are
important in tumor surveillance and protection against
infections.
CSE was also found to significantly inhibit the production
of TNF-α and IL-5 by iNKT cells (Fig. 3). Cytokine production
was examined after 72 h to determine if the inhibitory
effect observed persisted without the further addition of
CSE. Invariant NKT cells stimulated with αGalCer producedcomparable levels of IFN-γ when co-cultured for 72 h in the
absence or presence of CSE. The addition of CSE resulted in
significantly increased levels of IL-4 after 72 h compared to
iNKT cells incubated with CD1d-transfected C1R cells
loaded with αGalCer (Fig. 3B). This finding demonstrates
that iNKT cell cytokine production is inhibited in the
presence of CSE and subsequently altered in a Th2 manner
after 72 h. The production of a Th2-biased cytokine milieu
by iNKT cells has previously been reported in subjects with
cancer [18].
The iNKT cell lines expressed the activation-associated
surface molecules CD56 and CD69. These molecules were
increased following stimulation with αGalCer. The addition
of CSE to the cultures had no significant effect on the
expression of either activation markers suggesting the iNKT
cells were still activated by αGalCer (Fig. 2). Invariant NKT
cells can lyse target cells by perforin CD107 [32,33]. We
examined the expression of CD107 and observed that it was
upregulated in the presence of αGalCer-loaded CD1d cells.
This may be due to the specific lysing of CD1d-positive cells
by iNKT cells as previously described [32,33]. With the
addition of CSE, the upregulation of CD107 was inhibited
(Fig. 2). We have shown that CSE also inhibited CD107
expression in NK cells without affecting other NK cell
markers [9]. As a result of the inhibition of CD107-
upregulation we examined the effect of CSE on the iNKT
cell cytotoxic ability. We demonstrated the significant
inhibition of iNKT cell lysis of HeLa target cells both in the
absence (Fig. 4C) and presence (Fig. 4D) of αGalCer (Fig. 4).
This suggests further impairment of iNKT cell anti-tumor
activity due to exposure to CSE (IFN-γ production and tumor
lysis).
Figure 4 Investigation of CSE inhibition of iNKT cell cytotoxicity. Representative dot plots (A) showing the lysis of target cells by iNKT cells
and (B and C) bar graphs displaying the mean percentage lysis. The iNKT cells were cultured with CFSE labeled CD1d transfected C1R cells in
the absence or presence of 100 ng/mlαGalCer,with orwithout CSE for 4 h.Graphs are representative of 3 individual experiments. *=pb0.05.
234 A.E. Hogan et al.These findings demonstrate that cigarette smokers have a
reduction in the number of circulating iNKT cells and that
CSE directly alters iNKT cells anti-tumor activity.
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